» Articles » PMID: 33575473

Therapeutic Potential of IBP As an Autophagy Inducer for Treating Lung Cancer Via Blocking PAK1/Akt/mTOR Signaling

Overview
Publisher Cell Press
Date 2021 Feb 12
PMID 33575473
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Lung cancer is the most frequent and fatal malignancy in humans worldwide, yet novel successful drugs for control of this disease are still lacking. polysaccharides (IBPs) have been implicated in inhibiting diverse cancer types, but their functions in mitigating lung cancer are largely unknown. In this study, we identify a role of IBP in inhibiting lung cancer proliferation. We found that IBP significantly impedes the proliferation of lung cancer cells by inducing cytostatic macroautophagy both and . Mechanistically, IBP specifically promotes ubiquitination-mediated degradation of PAK1 (p21-activated kinase 1) and blocks its downstream Akt1/mTOR signaling pathway, leading to increased autophagic flux. In lung cancer xenografts in mice, IBP-induced cytostatic autophagy suppresses tumor development. Through site-directed mutational analysis, the underlying signaling augments ubiquitination via PAK1-ubiquitin interaction. Collectively, this work unravels the molecular mechanism underpinning IBP-induced cytostatic autophagy in lung cancer and characterizes IBP as a potential therapeutic agent for lung cancer treatment.

Citing Articles

Anti-Cancer Strategy Based on Changes in the Role of Autophagy Depending on the Survival Environment and Tumorigenesis Stages.

Lee M, Kim H Molecules. 2024; 29(21).

PMID: 39519774 PMC: 11547988. DOI: 10.3390/molecules29215134.


Biomarker discovery with quantum neural networks: a case-study in CTLA4-activation pathways.

Nguyen P BMC Bioinformatics. 2024; 25(1):149.

PMID: 38609844 PMC: 11265126. DOI: 10.1186/s12859-024-05755-0.


The roles of protein ubiquitination in tumorigenesis and targeted drug discovery in lung cancer.

Ye Z, Yang J, Jiang H, Zhan X Front Endocrinol (Lausanne). 2023; 14:1220108.

PMID: 37795365 PMC: 10546409. DOI: 10.3389/fendo.2023.1220108.


Implication of mTOR Signaling in NSCLC: Mechanisms and Therapeutic Perspectives.

Gargalionis A, Papavassiliou K, Papavassiliou A Cells. 2023; 12(15).

PMID: 37566093 PMC: 10416991. DOI: 10.3390/cells12152014.


PAK4-relevant proliferation reduced by cell autophagy via p53/mTOR/p-AKT signaling.

Li Q, Wang S, Wang W, Ye Y, Ling Y, Dai Y Transl Cancer Res. 2023; 12(3):461-472.

PMID: 37033362 PMC: 10080326. DOI: 10.21037/tcr-22-2272.


References
1.
Siegel R, Jemal A, Wender R, Gansler T, Ma J, Brawley O . An assessment of progress in cancer control. CA Cancer J Clin. 2018; 68(5):329-339. DOI: 10.3322/caac.21460. View

2.
Li Y, He S, He Z, Li M, Yang Y, Pang J . Plumbagin induces apoptotic and autophagic cell death through inhibition of the PI3K/Akt/mTOR pathway in human non-small cell lung cancer cells. Cancer Lett. 2013; 344(2):239-59. DOI: 10.1016/j.canlet.2013.11.001. View

3.
Liu Y, Tang J, Liu D, Zhang L, He Y, Li J . Increased autophagy in EOC re-ascites cells can inhibit cell death and promote drug resistance. Cell Death Dis. 2018; 9(4):419. PMC: 5856849. DOI: 10.1038/s41419-018-0449-5. View

4.
Chen Q, Jiao D, Wu Y, Chen J, Wang J, Tang X . MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway. Oncotarget. 2016; 7(14):18247-61. PMC: 4951285. DOI: 10.18632/oncotarget.7570. View

5.
Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View